Renal lymphomatous infiltration by mantle cell lymphoma: Treatment with chemoradiation and initiation of angiotensin converting enzyme (ACE) inhibitor for renal protection

Abstract

Background:

Mantle Cell Lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that often takes an aggressive course. Rarely, MCL may cause acute kidney injury (AKI) either by direct lymphomatous invasion or by paraneoplastic processes.

Case presentation:

We present a rare case of a 64-year-old-man with AKI caused by recurrent MCL infiltrating into the bilateral renal collecting systems who was treated with renal-directed low-dose radiation therapy (RT; 4 Gy) and concurrent systemic chemotherapy. In order to prevent possible radiation-induced damage to the kidneys, he was started on captopril prior to start of RT. After RT, his renal function continued to improve until returning to baseline.

Conclusion:

Renal-directed RT with a low-dose of radiation (4 Gy) was used successfully to treat renal MCL infiltration and reverse the effects of AKI. We would also like to highlight the potential use of angiotensin converting enzyme (ACE) inhibitors to decrease the chances of radiation-induced kidney injury.

Keywords

Acute kidney injury mantle cell lymphoma renal lymphomatous infiltration chemoradiation radiation induced kidney injury angiotensin converting enzyme inhibitors

Get full access to this article

View all access options for this article.

References

Ettleson

Bongers

Vitale

, et al. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: a case report. J Oncol Pharm Pract 2019; 25(3): 731–734.

Da’As

Polliack

Cohen

, et al. Kidney involvement and renal manifestations in non-hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 2001; 67(3): 158–164.

Ning

Pinnix

Chapman

, et al. Low-dose radiation (4 gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv 2019; 3(13): 2035–2039.

Kala

Radiation-induced kidney injury. J Onco-Nephrol 2019; 3(3): 160–167.

Dawson

Kavanagh

Paulino

, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 2010; 76(3): S108– S115.

Cheng

Schultheiss

Wong

JYC

. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 2008; 71(5): 1436–1443.

Moulder

Fish

Cohen

EP.

Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy. Bone Marrow Transplant 1997; 19(7): 729–735.

Cohen

Fish

Moulder

JE.

Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy. Curr Drug Targets 2012; 11(11): 1423–1429.

Medhora

Gao

, et al. Model development and use of ace inhibitors for preclinical mitigation of radiation-induced injury to multiple organs. Radiat Res 2014; 182(5): 545–555.

10.

Cohen

Irving

Drobyski

, et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys 2008; 70(5): 1546–1551.